1차 유효성 평가변수는 DCV 및 ASV 치료 완료 후 24주에 HCV RNA가 25 IU/mL 미만인 환자의 비율이었다.
The primary efficacy endpoint was the proportion of patients with HCV RNA <25 IU/mL at 24 weeks after completion of DCV and ASV treatment.